LAG3 and lung carcinoma: In metastatic hormone-receptor positive breast cancer, progression-free survival (PFS) and OS was better for patients with detectable sLAG3 levels at diagnosis [15], while contrastingly in lung cancer, high sLAG3 levels resulted in a significantly shorter relapse free survival [31].